Immunome Q2 net loss $5.6M; merger with Morphimmune and $125M PIPE deal announced

Immunome Inc.

2023-Q2 EPS reported -$0.81 revenue$6,627,000

Q2 net loss $5.6M ($0.46 per share) on $4.3M AbbVie collaboration revenue; R&D $5.7M, G&A $4.2M.
Cash and cash equivalents $38.4M as of June 30, 2023.
Definitive merger agreement with Morphimmune to combine platforms, expected close by end of 2023.
Clay Siegall, ex-Seagen CEO, to serve as Chairman and CEO of combined company.
Concurrent $125M private placement from institutional investors to support 3 IND filings within 18 months post-close.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Immunome Inc. reported the second quarter ended June 30, 2023 results: net income $5.6 million, or $0.46 per share, EPS $0.46 per share.

Period: the second quarter ended June 30, 2023
Net income: $5.6 million, or $0.46 per share
EPS: $0.46 per share
Result: reported results

Exact text from the filing

Net loss for the three months ended June 30, 2023 was $5.6 million, or $0.46 per share.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunome Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-089110

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.